BRPI0814363A2 - Produtos fármacos de interferon de liberação controlada e tratamento de infecção por hcv usando os mesmos - Google Patents

Produtos fármacos de interferon de liberação controlada e tratamento de infecção por hcv usando os mesmos

Info

Publication number
BRPI0814363A2
BRPI0814363A2 BRPI0814363-3A2A BRPI0814363A BRPI0814363A2 BR PI0814363 A2 BRPI0814363 A2 BR PI0814363A2 BR PI0814363 A BRPI0814363 A BR PI0814363A BR PI0814363 A2 BRPI0814363 A2 BR PI0814363A2
Authority
BR
Brazil
Prior art keywords
interferon
same
controlled release
hcv infection
release drug
Prior art date
Application number
BRPI0814363-3A2A
Other languages
English (en)
Inventor
David Gelvin Spencer
John Elliot Humphries
Leonardus Gerardus Jozef De Leede
Rudolf Verrijk
Original Assignee
Biolex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolex Therapeutics Inc filed Critical Biolex Therapeutics Inc
Publication of BRPI0814363A2 publication Critical patent/BRPI0814363A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI0814363-3A2A 2007-07-25 2008-07-25 Produtos fármacos de interferon de liberação controlada e tratamento de infecção por hcv usando os mesmos BRPI0814363A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95187907P 2007-07-25 2007-07-25
US95214007P 2007-07-26 2007-07-26
US97833007P 2007-10-08 2007-10-08
US98552607P 2007-11-05 2007-11-05
PCT/US2008/071191 WO2009015336A2 (en) 2007-07-25 2008-07-25 Controlled release interferon drug products and treatment of hcv infection using same

Publications (1)

Publication Number Publication Date
BRPI0814363A2 true BRPI0814363A2 (pt) 2015-01-27

Family

ID=40282165

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814363-3A2A BRPI0814363A2 (pt) 2007-07-25 2008-07-25 Produtos fármacos de interferon de liberação controlada e tratamento de infecção por hcv usando os mesmos

Country Status (11)

Country Link
US (1) US8137661B2 (pt)
EP (1) EP2175865A4 (pt)
JP (1) JP2010534681A (pt)
KR (1) KR20100056479A (pt)
CN (1) CN101820887A (pt)
AU (1) AU2008279087A1 (pt)
BR (1) BRPI0814363A2 (pt)
CA (1) CA2694440A1 (pt)
MX (1) MX2010000965A (pt)
WO (1) WO2009015336A2 (pt)
ZA (1) ZA201000681B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010042834A1 (en) * 2008-10-09 2010-04-15 Anadys Pharmaceuticals, Inc. A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
AU2011330701A1 (en) 2010-11-19 2013-07-04 Venus Remedies Limited Novel conjugates for targeted drug delivery
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
DE112012003510T5 (de) 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
EP2809334A4 (en) * 2012-02-01 2015-06-24 Abbvie Inc ONCE DAILY TREATMENT OF HEPATITIS C WITH RIBAVIRIN AND TARIBAVIRIN
WO2013168179A2 (en) * 2012-04-03 2013-11-14 Rubicon Research Private Limited Controlled release pharmaceutical formulations of antiviral agents
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
WO2021009332A1 (en) * 2019-07-18 2021-01-21 Enyo Pharma Method for decreasing adverse-effects of interferon
EP4135845A2 (en) * 2020-04-14 2023-02-22 Amerimmune, LLC Treatment for diseases caused by rna viruses

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410697B1 (en) * 1979-04-20 2002-06-25 Schering Corporation Process for purifying human leukocyte interferon
US6835557B1 (en) * 1980-01-08 2004-12-28 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing human interferon-like polypeptides
US6610830B1 (en) * 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
US4749576A (en) * 1984-05-10 1988-06-07 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
ES2214551T3 (es) 1995-11-02 2004-09-16 Schering Corporation Terapia de infusion continua de citocinas a baja dosis.
US5980948A (en) 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
US6153211A (en) * 1997-07-18 2000-11-28 Infimed, Inc. Biodegradable macromers for the controlled release of biologically active substances
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
PT903148E (pt) 1997-09-21 2002-02-28 Schering Corp Terapia de combinacao para a erradicacao de rna de hcv detectavel em doentes tendo infeccao cronica pelo virus da hepatite c
US6472373B1 (en) * 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
DE69901321T2 (de) 1998-05-15 2002-12-12 Schering Corp., Kenilworth Kombinationstherapie enthaltend Ribavirin und Interferon alpha bei Patienten mit chronischer Hepatitis C Infektion, die nicht antiviral vorbehandelt sind
US6194006B1 (en) * 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US20030206928A1 (en) * 1999-04-07 2003-11-06 Pertti Tormala Bioactive, bioabsorbable surgical polyethylene glycol and polybutylene terephtalate copolymer composites and devices
US6465425B1 (en) * 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
NZ523912A (en) * 2000-07-31 2005-03-24 Biolex Inc Expression of biologically active polypeptides in duckweed
US7959910B2 (en) * 2000-07-31 2011-06-14 Biolex Therapeutics, Inc. C-terminally truncated interferon alpha variants
GB0018968D0 (en) 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
CA2466998A1 (en) 2001-11-12 2003-05-22 Alkermes Controlled Therapeutics, Inc. Biocompatible polymer blends and uses thereof
RU2346950C2 (ru) 2003-01-28 2009-02-20 Академис Зикенхейс Лейден Пептидные ингибиторы токсинов, производные ll-37
US20050269364A1 (en) * 2004-04-30 2005-12-08 Gibson Rayce D Inflatable seal for bin discharge system
EP1621205A1 (en) 2004-07-28 2006-02-01 OctoPlus Technologies B.V. Antimicrobial peptides derived from CAP18
EP1679065A1 (en) * 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
US20070021434A1 (en) * 2005-06-24 2007-01-25 Migenix Inc. Non-nucleoside anti-hepacivirus agents and uses thereof
MX2008008723A (es) * 2006-01-09 2008-09-26 Romark Lab Lc Tratamiento de la hepatitis viral.

Also Published As

Publication number Publication date
CN101820887A (zh) 2010-09-01
MX2010000965A (es) 2010-03-09
WO2009015336A3 (en) 2009-03-19
EP2175865A2 (en) 2010-04-21
JP2010534681A (ja) 2010-11-11
WO2009015336A2 (en) 2009-01-29
AU2008279087A1 (en) 2009-01-29
ZA201000681B (en) 2013-07-31
CA2694440A1 (en) 2009-01-29
US8137661B2 (en) 2012-03-20
EP2175865A4 (en) 2012-01-11
KR20100056479A (ko) 2010-05-27
US20090068280A1 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
ZA201001585B (en) Spiropyrrolidines and their use against hcv and hiv infection
ZA201000681B (en) Controlled release interferon drug products and treatment of hcv infection using same
ATE522216T1 (de) Verwendung von 2-6-(3-amin-piperidin-1-yl)-3- methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1- ylmethyl-4-fluor-benzonitril zur behandlung von diabetes, krebs, autoimmunerkrankungen und hiv- infektionen
NO20070988L (no) Vaksine for forebygging og behandling av HIV-infeksjon
BRPI0807544A2 (pt) Sólido farmacêutico e dose de vacina
EP1933936A4 (en) IMPREGNATED ENVELOPE OF MEDICAMENT
IL200116A0 (en) Compounds and pharmaceutical compositions for the treatment of viral infections
PL2281831T3 (pl) Szczepionka przeciw wirusowi ospy wietrznej i półpaśca
SI2878297T1 (sl) Zdravila za zdravljenje ali preprečevanje fibroznih bolezni
EP2132133A4 (en) RELEASE OF PARTICULATE ACTIVE SUBSTANCES
DK2155758T3 (da) Tetrahydrofuro[3,4-d]dioxolanforbindelser til anvendelse i behandlingen af virusinfektioner og cancer
BRPI0822625A2 (pt) "dispositivo espaçador modular para o tratamento de infecções por próteses"
HRP20130114T1 (xx) Farmaceutski oblik s brzim oslobađanjem sinakalcet hci
DK1983964T3 (da) Anordning til indgivelse af lægemiddel
EP2175817A4 (en) ABSORBENT ARTICLE ADHERING TO THE BODY
IL195272A0 (en) Methods and compositions for the treatment of viral infections
ATE533774T1 (de) Neuartige nukleosidanaloge zur behandlung von virusinfektionen
IS7564A (is) Lyfjablanda með breytta losun
BRPI0819839A2 (pt) Uso de anticorpo humano capaz de neutralizar o vírus da hepatite b para a prevenção ou tratamento da infecção por vírus da hepatite b
BRPI0812015A2 (pt) Membro de reforço de borracha e produto de borracha utilizando o mesmo.
GB2411354B (en) Use of Scutellaria for the treatment of viral infections
ATE539155T1 (de) Targets und zusammensetzungen zur therapeutischen intervention bei hiv-infektion
DK3156057T3 (da) Delmopinol-belagt dyretyggeartikel til anvendelse til forebyggelsen eller behandlingen af halitosis
AP2081A (en) Oligomeric peptides and their use for the treatment of HIV infections
PT2341900T (pt) Produto medicinal e tratamento

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.